AB Science ABSCF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.76
- Day Range
- $2.70–2.70
- 52-Week Range
- $0.00–4.46
- Bid/Ask
- $0.00 / $14.00
- Market Cap
- $133.71 Mil
- Volume/Avg
- 1,452 / 33,201
Key Statistics
- Price/Earnings (Normalized)
- 1.67
- Price/Sales
- 210.44
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing of protein kinase inhibitors. It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 89
- Website
- https://www.ab-science.com
Comparables
Valuation
|
Metric
|
ABSCF
|
VRDN
|
TGTX
|
|---|---|---|---|
Price/Earnings (Normalized) | 1.67 | — | 17.99 |
Price/Book Value | — | 2.91 | 13.44 |
Price/Sales | 210.44 | 1,810.15 | 9.06 |
Price/Cash Flow | — | — | 39.74 |
Price/Earnings
ABSCF
VRDN
TGTX
Financial Strength
|
Metric
|
ABSCF
|
VRDN
|
TGTX
|
|---|---|---|---|
Quick Ratio | 1.39 | 17.93 | 5.00 |
Current Ratio | 1.43 | 18.26 | 5.92 |
Interest Coverage | −6.34 | −137.76 | 2.04 |
Quick Ratio
ABSCF
VRDN
TGTX
Profitability
|
Metric
|
ABSCF
|
VRDN
|
TGTX
|
|---|---|---|---|
Return on Assets (Normalized) | −62.36% | −42.76% | 19.44% |
Return on Equity (Normalized) | — | −82.42% | 54.76% |
Return on Invested Capital (Normalized) | — | −50.70% | 35.76% |
Return on Assets
ABSCF
VRDN
TGTX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Hqwqqgnjm | Msdftt | $69.8 Bil | |
ZTS
| Zoetis Inc Class A | Zggxvqwnvj | Ftnp | $68.9 Bil | |
HLN
| Haleon PLC ADR | Rtvvzvhwz | Xsck | $37.7 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Lfqskyt | Ljpr | $14.8 Bil | |
VTRS
| Viatris Inc | Dptpxgdp | Kwcpw | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Kpqcqqnl | Btnq | $11.9 Bil | |
CTLT
| Catalent Inc | Gmkyqtvy | Ntmxdyy | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Kzcbnyq | Ldsdw | $4.2 Bil | |
CURLF
| Curaleaf Holdings Inc | Qnlcxbhk | Tkmpd | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Ltvxrjbbp | Ydfmyv | $3.5 Bil |